Calcitonin gene-related peptide (hCGRPα) binding sites in the nucleus accumbens. Atypical structural requirements and marked phylogenic differences

doi:10.1016/0006-8993(91)90686-P

Brain Research

Volume 539, Issue 1, 18 January 1991, Pages 59-66

https://doi.org/10.1016/0006-8993(91)90686-P Get rights and content

Abstract

The distribution of [¹²⁵I]hCGRPα binding sites was studied in tissue sections from rat brain and, at the level of the nucleus accumbens in the brains of 6 other species. In the rat, very high levels of binding were found in the nucleus accumbens, the amygdaloid complex and mammillary body while high amounts were localized to the superficial layers of the superior colliculus, temporal cortex, cerebellum (molecular layer), frontal cortex and inferior olive. Moderate densities of [¹²⁵I]hCGRPα binding were observed in the medial geniculate nucleus, inferior colliculus and substantia nigra. Regional competition studies in rat brain showed that salmon calcitonin was almost as effective as hCGRPα in competing for [¹²⁵I]hCGRPα binding sites in the nucleus accumbens but was mostly inactive in other regions such as the mesolimbic cortex and the striatum. On the basis of their atypical sensitivity to salmon calcitonin, [¹²⁵I]hCGRPα binding sites in the rat nucleus accumbens, which appear between postnatal days 4 and 7, do not seem to correspond to either the CGRP₁ or CGRP₂ receptor subtypes⁶. Marked species differences were observed in the distribution of [¹²⁵I]hCGRPα binding sites, especially in the nucleus accumbens. In the mouse, low densities of hCGRPα sites were observed in striatum and fronto-parietal cortex while low to moderate levels were found in the medial and posterior aspects of the nucleus accumbens. A similar distribution was seen in the guinea pig brain albeit of generally higher density. In the rat, very high amounts of [¹²⁵I]hCGRPα binding were seen in the nucleus accumbens while lower levels were found in the striatum and certain cortical areas. In the rabbit, a very high density of [¹²⁵I]hCGRPα labelling was observed in the nucleus accumbens, caudate nucleus and putamen, whereas low levels were present in the cortex. A very high density of [¹²⁵I]hCGRPα binding sites were localized throughout the basal ganglia and the cortical ribbon of pig brain. Finally, in both monkey and human brain, only low densities of binding sites were seen in the nucleus accumbens and surrounding structures. Thus, it seems that the appearance of [¹²⁵I]hCGRPα binding sites in the nucleus accumbens, of unique pharmacological profile in the rat, is highly species dependent.

References (35)

CrawleyJ.N. et al.
Topographical analysis of nucleus accumbens sites at which cholecystokinin potentiates dopamine-induced hyperlocomotion in the rat
Brain Research
(1985)
Ho¨kfeltT. et al.
A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: evidence from immunohistochemistry combined with retrograde tracing
Neuroscience
(1980)
HughesJ.J. et al.
Intraventricular calcitonin gene-related peptide inhibits gastric acid section
Peptides
(1987)
InagakiS. et al.
Ontogeny of calcitonin gene-related peptide-immunoreactive structures in the rat forebrain and diencephalon
Dev. Brain Res.
(1988)
JolicoeurF.B. et al.
Neurobehavioral effects of calcitonin gene-related peptide
Soc. Neurosc. Abstr.
(1989)
KiyamaH. et al.
Ontogeny of cholecystokinin-8 containing neuron system of the rat: an immunohistochemical analysis. II. Lower brain stem
Neuroscience
(1983)
KrahnD.D. et al.
Effects of calcitonin gene-related peptide on food intake
Peptides
(1984)
KubotaY. et al.
Ontogeny of the calcitonin gene-related peptide in the nervous system of rat brain stem: an immunohistochemical analysis
Neuroscience
(1988)
NakamutaH. et al.
Binding sites of calcitonin gene-related peptide (CGRP). Abundant occurrence in visceral organs
Jpn. J. Pharmacol.
(1986)
OkimuraY. et al.
Calcitonin gene-related peptide-like immunoreactivity in the central nervous system and peripheral organs of rat
Reg. Pept.
(1987)

PaxinosG. et al.

The Rat Brain in Sterotaxic Coordinates

(1982)

SeifertH. et al.

Binding sites for calcitonin gene-related peptide in distinct areas of rat brain

Brain Research

(1985)

SeroogyK.B. et al.

A subpopulation of dopaminergic neurons in rat ventral mesencephalon contains both neurotensin and cholecystokinin

Brain Research

(1988)

SextonP.M. et al.

Localization of binding sites of calcitonin gene-related peptide in rat brain by in vitro autoradiography

Neuroscience

(1986)

SextonP.M. et al.

Evidence for a new subclass of calcitonin gene-related peptide binding site in rat brain

Neurochem. Int.

(1988)

ShimadaS. et al.

Calcitonin gene-related peptide projection from the parabrachial area to the fore brain and diencephalon in the rat: an immunohistochemical analysis

Neuroscience

(1985)

SkofitschG. et al.

Calcitonin gene-related peptide: detailed immunohistochemical distribution in the central nervous system

Peptides

(1985)

Cited by (52)

Expression of calcitonin gene-related peptide receptor subunits in cultured neurons following morphine treatment
2013, Neuroscience Letters
Citation Excerpt :
Our data showed that, although CRLR not altered, RAMP1 subunit of CGRP receptor time-dependently increased in striatal culture after morphine administration, similar in part to that happened in the spinal cord. Additionally, cerebellum expressed more CGRP receptors than other brain regions in human [5]. Cerebellar activation was observed during migraine attack, and CRLR/RAMP1 were detected on the surface of cell bodies and processes of Purkinje cells [6].
Calcitonin gene-related peptide (CGRP) has been implicated in pain transmission and morphine tolerance. Although the release of CGRP is well observed in pain-related regions after chronic morphine treatment, a lack of evidence is obvious for the expression of CGRP-receptor subunits, calcitonin receptor-like receptor (CRLR) and receptor activity-modifying protein 1 (RAMP1) in the brain. In this study, we investigated in vitro the time-course of the expression of CRLR and RAMP1 following morphine administration, and compared their changes among striatal, cerebellar, cortical and the spinal cord neurons. The levels of CRLR showed no significant changes in striatal cultures during morphine treatment, while the levels of RAMP1 time-dependently increased. Decrease in the content of RAMP1 was detected in cerebellar cultures. Apart from these facts, no significant changes of CRLR or RAMP1 were detected in any other cultures. The changes in the level of CRLR on the cell membrane were examined. Significant increases of surface CRLR were detected in both striatal and cerebellar neurons after morphine treatment, while cortical neurons not. It is concluded that the expression of gross and surface CRLR and RAMP1 were differentially regulated in primary neuronal cultures following morphine treatments, indicating the involvement of CGRP receptor in morphine associated functions.
Modulation of voltage-dependent calcium channels by neurotransmitters and neuropeptides in parasympathetic submandibular ganglion neurons
2004, Archives of Oral Biology
Citation Excerpt :
This peptide is often co-localised with SP,10,108–111 from nerve ending112 and to a lesser degree with PACAP.113 CGRP receptors are belong to the family of 7TM-GPCRs.114–116 CGRP receptors are widely distributed throughout the nervous system and have been studied in several species.116
The control of saliva secretion is mainly under parasympathetic control, although there also could be a sympathetic component. Sympathetic nerves are held to have a limited action in secretion in submandibular glands because, on electrical stimulation, only a very small increase to the normal background, basal secretion occurs. Parasympathetic stimulation, on the other hand, caused a good flow of saliva with moderate secretion of acinar mucin, plus an extensive secretion of granules from the granular tubules. The submandibular ganglion (SMG) is a parasympathetic ganglion which receives inputs from preganglionic cholinergic neurons, and innervates the submandibular salivary gland to control saliva secretion. Neurotransmitters and neuropeptides acting via G-protein coupled receptors (GPCRs) change the electrical excitability of neurons. In these neurons, many neurotransmitters and neuropeptides modulate voltage-dependent calcium channels (VDCCs). The modulation is mediated by a family of GPCRs acting either directly through the membrane delimited G-proteins or through second messengers. However, the mechanism of modulation and the signal transduction pathway linked to an individual GPCRs depend on the animal species. This review reports how neurotransmitters and neuropeptides modulate VDCCs and how these modulatory actions are integrated in SMG systems. The action of neurotransmitters and neuropeptides on VDCCs may provide a mechanism for regulating SMG excitability and also provide a cellular mechanism of a variety of neuronal Ca²⁺-dependent processes.
Receptor autoradiography as mean to explore the possible functional relevance of neuropeptides: Focus on new agonists and antagonists to study natriuretic peptides, neuropeptide Y and calcitonin gene-related peptides
2004, Peptides
Over the past 20 years, receptor autoradiography has proven most useful to provide clues as to the role of various families of peptides expressed in the brain. Early on, we used this method to investigate the possible roles of various brain peptides. Natriuretic peptide (NP), neuropeptide Y (NPY) and calcitonin (CT) peptide families are widely distributed in the peripheral and central nervous system and induced multiple biological effects by activating plasma membrane receptor proteins. The NP family includes atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP). The NPY family is composed of at least three peptides NPY, peptide YY (PYY) and the pancreatic polypeptides (PPs). The CT family includes CT, calcitonin gene-related peptide (CGRP), amylin (AMY), adrenomedullin (AM) and two newly isolated peptides, intermedin and calcitonin receptor-stimulating peptide (CRSP). Using quantitative receptor autoradiography as well as selective agonists and antagonists for each peptide family, in vivo and in vitro assays revealed complex pharmacological responses and radioligand binding profile. The existence of heterogeneous populations of NP, NPY and CT/CGRP receptors has been confirmed by cloning. Three NP receptors have been cloned. One is a single-transmembrane clearance receptor (NPR-C) while the other two known as CG-A (or NPR-A) and CG-B (or NPR-B) are coupled to guanylate cyclase. Five NPY receptors have been cloned designated as Y₁, Y₂, Y₄, Y₅ and y₆. All NPY receptors belong to the seven-transmembrane G-protein coupled receptors family (GPCRs; subfamily type I). CGRP, AMY and AM receptors are complexes which include a GPCR (the CT receptor or CTR and calcitonin receptor-like receptor or CRLR) and a single-transmembrane domain protein known as receptor-activity-modifying-proteins (RAMPs) as well as an intracellular protein named receptor-component-protein (RCP). We review here tools that are currently available in order to target each NP, NPY and CT/CGRP receptor subtype and establish their respective pathophysiological relevance.
Calcitonin gene-related peptide-induced suppression of atrial natriuretic peptide release through receptors for CGRP<inf>1</inf> but not for calcitonin and amylin
2004, European Journal of Pharmacology
Calcitonin gene-related peptide (CGRP), a 37-amino acid neuropeptide, is found in the central nervous system as well as in the heart. CGRP shows high sequence homology with amylin, salmon calcitonin, and adrenomedullin. This study aimed to investigate the effect of CGRP on atrial hemodynamics and atrial natriuretic peptide (ANP) release by using isolated perfused beating left atria and to identify its receptor subtypes. Rat α-CGRP (0.1, 1, 10, or 100 nM) increased atrial contractility and suppressed the release of ANP in a concentration-dependent manner. However, cys-CGRP (1 μM), a CGRP₂ receptor agonist, slightly decreased ANP release without positive inotropism. Human α-CGRP (1 nM) showed an effect on ANP release similar to that of rat α-CGRP with potent positive inotropism. However, salmon and rat calcitonin (1 μM) caused a slight decrease or no change in ANP release. Pretreatment with a receptor antagonist for CGRP₁ [rat α-CGRP-(8–37)] blocked rat α-CGRP-induced suppression of ANP release and positive inotropism, whereas the antagonists for salmon or amylin did not. Therefore, we suggest that rat α-CGRP causes a suppression of ANP release with positive inotropism through the receptor for CGRP₁ but not that for calcitonin and amylin.
Autoradiographic localization of <sup>125</sup>i[Tyr<sup>14</sup>] nociceptin/orphanin FQ binding sites in macaque primate cns
2003, Neuroscience
Nociceptin/orphanin FQ (N/OFQ) is a recently identified neuropeptide that has been implicated in a multitude of CNS functions. These include nociception, feeding, cognition, locomotion, stress and neuroendocrine control. The endogenous receptor for this ligand is the nociceptin/orphanin FQ peptide (NOP) receptor. The distribution of NOP in rodent has been widely reported by the use of in situ hybridization, immunohistochemistry and autoradiographic radioligand binding but less is known of its localization in higher species. We have therefore sought to optimize and determine the distribution of ¹²⁵I[Tyr¹⁴]N/OFQ binding sites in macaque primate brain and spinal cord. Highest levels of binding were observed in neocortical areas, hippocampus, amygdala, caudate nucleus and putamen, medial thalamic nuclei and superficial laminae of the superior colliculus. These novel data present for the first time, the distribution of N/OFQ receptors in non-human primate CNS and, by comparison with localization in the rat, reveal that species differences may exist in the distribution of this neuropeptide receptor. These data have important implications regarding the roles of N/OFQ across species and may have ramifications in the interpretation of preclinical pharmacological studies.
Localization of functional calcitonin gene-related peptide binding sites in a subpopulation of cultured dorsal root ganglion neurons
2002, Neuroscience
In this study we investigated whether cultured dorsal root ganglion (DRG) neurons from the adult rat express binding sites for calcitonin gene-related peptide (CGRP). These were identified on fixed cells by using CGRP labeled at the N-terminal site with 1.4-nm gold particles. After 1 day in culture, about 20% of small to medium-sized DRG neurons showed CGRP-gold binding. Binding of CGRP-gold was dose-dependently reduced by coadministration of CGRP. The calcium imaging technique in living cells revealed that the bath administration of CGRP evoked an increase of the intracellular calcium in up to 30% of the DRG neurons tested. Both depletion of intracellular calcium stores by thapsigargin or using a calcium-free medium blocked the CGRP-mediated increase of cytosolic calcium in most neurons. Thus intracellular and extracellular sources of calcium are relevant for the CGRP response. Using the whole-cell patch-clamp technique, about 30% of the neurons were found to exhibit an inward current and a depolarization upon administration of CGRP close to the neurons. Immunocytochemical double-labeling techniques showed that most of the CGRP-gold binding sites were expressed in unmyelinated (neurofilament 200-negative) DRG neurons. Most of the neurons with CGRP-gold binding sites also expressed the tyrosine kinase A receptor, and all of them showed CGRP-like immunoreactivity.
This study shows, therefore, that a subpopulation of unmyelinated, peptidergic primary afferent neurons express CGRP binding sites that can be activated by CGRP in an excitatory direction. The binding sites may serve as autoreceptors because all of these neurons also synthesize CGRP. The activation of CGRP binding sites may sensitize primary afferent neurons and influence the release of mediators.

View all citing articles on Scopus

View full text

Calcitonin gene-related peptide (hCGRPα) binding sites in the nucleus accumbens. Atypical structural requirements and marked phylogenic differences

Abstract

Brain Research

Neuroscience

Peptides

Dev. Brain Res.

Soc. Neurosc. Abstr.

Neuroscience

Peptides

Neuroscience

Jpn. J. Pharmacol.

Reg. Pept.

Brain Research

Brain Research

Neuroscience

Neurochem. Int.

Neuroscience

Peptides